Home Cart Sign in  
Chemical Structure| 183319-69-9 Chemical Structure| 183319-69-9

Structure of Erlotinib HCl
CAS No.: 183319-69-9

Chemical Structure| 183319-69-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM and acts as a click chemistry reagent containing an alkyne group, capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing azide groups.

Synonyms: CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Erlotinib HCl

CAS No. :183319-69-9
Formula : C22H24ClN3O4
M.W : 429.90
SMILES Code : COCCOC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3)=C2C=C1OCCOC.[H]Cl
Synonyms :
CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774
MDL No. :MFCD07781272
InChI Key :GTTBEUCJPZQMDZ-UHFFFAOYSA-N
Pubchem ID :176871

Safety of Erlotinib HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335-H412
Precautionary Statements:P261-P273-P305+P351+P338

Related Pathways of Erlotinib HCl

RTK
JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HCC4006rErlo0.5 0.5 µM 24 h To investigate the effect of Erlotinib on CIP2A protein levels in HCC4006rErlo0.5 cells, it was found that Erlotinib did not affect CIP2A levels. PMC8103245
HCC4006 0.5 µM 24 h To investigate the effect of Erlotinib on CIP2A protein levels in HCC4006 cells, it was found that Erlotinib significantly reduced CIP2A levels, leading to PP2A activation and Akt dephosphorylation. PMC8103245
HCC827/ER cells 7.20 μM HCC827/ER cells exhibited resistance to erlotinib PMC6331022
PC9/ER cells >10 μM PC9/ER cells exhibited strong resistance to erlotinib PMC6331022

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice TNBC xenograft model Intratumoral injection 40 mg/kg Every two days for approximately 4 weeks PDZK1 overexpression enhanced the inhibitory effect of erlotinib on tumor proliferation. PMC11009252

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04172779 Cirrhosis, Liver PHASE2 NOT_YET_RECRUITING 2025-06-30 -
NCT00749892 Recurrent Bladder Urothelial C... More >>arcinoma|Recurrent Renal Pelvis Urothelial Carcinoma|Recurrent Ureter Urothelial Carcinoma|Recurrent Urethral Urothelial Carcinoma|Stage 0a Bladder Cancer AJCC v8|Stage 0a Renal Pelvis Cancer AJCC v8|Stage 0a Ureter Cancer AJCC v8|Stage 0a Urethral Cancer AJCC v8|Stage 0is Bladder Cancer AJCC v8|Stage 0is Renal Pelvis Cancer AJCC v8|Stage 0is Ureter Cancer AJCC v8|Stage 0is Urethral Cancer AJCC v8|Stage II Bladder Cancer AJCC v8|Stage II Renal Pelvis Cancer AJCC v8|Stage II Ureter Cancer AJCC v8|Stage II Urethral Cancer AJCC v8|Stage III Renal Pelvis Cancer AJCC v8|Stage III Ureter Cancer AJCC v8|Stage III Urethral Cancer AJCC v8|Stage IIIA Bladder Cancer AJCC v8 Less << PHASE2 COMPLETED 2019-11-26 M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less <<
NCT03074864 Non-small Cell Lung Cancer|Epi... More >>dermal Growth Factor Receptor Less << PHASE2|PHASE3 UNKNOWN 2020-06-30 Guangdong General Hospital, Gu... More >>angzhou, Guangdong, 510080, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.33mL

0.47mL

0.23mL

11.63mL

2.33mL

1.16mL

23.26mL

4.65mL

2.33mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories